A Naturally Occurring HER2 Carboxy-Terminal Fragment Promotes Mammary Tumor Growth and Metastasis

REFERENCES

• Anido, J., M. Scaltriti, J. J. Bech Serra, B. S. Josefat, F. Rojo Todo, J. Baselga, and J. Arribas. 2006. Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J. 25:3234–3244.
   PubMed Web of Science ®Google Scholar
• Arribas, J., and A. Borroto. 2002. Protein ectodomain shedding. Chem. Rev. 102:4627–4638.
   PubMed Web of Science ®Google Scholar
• Black, S. D. 1992. Membrane topology of the mammalian P450 cytochromes. FASEB J. 6:680–685.
   PubMed Web of Science ®Google Scholar
• Brantley-Sieders, D. M., G. Zhuang, D. Hicks, W. B. Fang, Y. Hwang, J. M. Cates, K. Coffman, D. Jackson, E. Bruckheimer, R. S. Muraoka-Cook, and J. Chen. 2008. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J. Clin. Investig. 118:64–78.
   PubMed Web of Science ®Google Scholar
• Burgess, A. W., H.-S. Cho, C. Eigenbrot, K. M. Ferguson, T. P. J. Garrett, D. J. Leahy, M. A. Lemmon, M. X. Sliwkowski, C. W. Ward, and S. Yokoyama. 2003. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol. Cell 12:541–552.
   PubMed Web of Science ®Google Scholar
• Christianson, T. A., J. K. Doherty, Y. J. Lin, E. E. Ramsey, R. Holmes, E. J. Keenan, and G. M. Clinton. 1998. NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res. 58:5123–5129.
   PubMed Web of Science ®Google Scholar
• Citri, A., and Y. Yarden. 2006. EGF-ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell Biol. 7:505–516.
   PubMed Web of Science ®Google Scholar
• Codony-Servat, J., J. Albanell, J. C. Lopez-Talavera, J. Arribas, and J. Baselga. 1999. Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res. 59:1196–1201.
   PubMed Web of Science ®Google Scholar
• Ding, X., L. Y. Yang, G. W. Huang, W. Wang, and W. Q. Lu. 2004. ADAM17 mRNA expression and pathological features of hepatocellular carcinoma. World J. Gastroenterol. 10:2735–2739.
   PubMed Web of Science ®Google Scholar
• Garrett, T. P., N. M. McKern, M. Lou, T. C. Elleman, T. E. Adams, G. O. Lovrecz, M. Kofler, R. N. Jorissen, E. C. Nice, A. W. Burgess, and C. W. Ward. 2003. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol. Cell 11:495–505.
   PubMed Web of Science ®Google Scholar
• Gentile, A., and P. M. Comoglio. 2004. Invasive growth: a genetic program. Int. J. Dev. Biol. 48:451–456.
   PubMedGoogle Scholar
• Giri, D. K., M. Ali-Seyed, L. Y. Li, D. F. Lee, P. Ling, G. Bartholomeusz, S. C. Wang, and M. C. Hung. 2005. Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell surface receptor. Mol. Cell. Biol. 25:11005–11018.
   PubMed Web of Science ®Google Scholar
• Gupta, G. P., D. X. Nguyen, A. C. Chiang, P. D. Bos, J. Y. Kim, C. Nadal, R. R. Gomis, K. Manova-Todorova, and J. Massague. 2007. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 446:765–770.
   PubMed Web of Science ®Google Scholar
• Guy, C. T., M. A. Webster, M. Schaller, T. J. Parsons, R. D. Cardiff, and W. J. Muller. 1992. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA 89:10578–10582.
   PubMed Web of Science ®Google Scholar
• Hsu, S. C., and M. C. Hung. 2007. Characterization of a novel tripartite nuclear localization sequence in the EGFR family. J. Biol. Chem. 282:10432–10440.
   PubMed Web of Science ®Google Scholar
• Hynes, N. E., and H. A. Lane. 2005. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5:341–354.
   PubMed Web of Science ®Google Scholar
• Kang, Y., P. M. Siegel, W. Shu, M. Drobnjak, S. M. Kakonen, C. Cordon-Cardo, T. A. Guise, and J. Massague. 2003. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3:537–549.
   PubMed Web of Science ®Google Scholar
• Kochetov, A. V. 2008. Alternative translation start sites and hidden coding potential of eukaryotic mRNAs. Bioessays 30:683–691.
   PubMedGoogle Scholar
• Kwong, K. Y., and M. C. Hung. 1998. A novel splice variant of HER2 with increased transformation activity. Mol. Carcinog. 23:62–68.
   PubMed Web of Science ®Google Scholar
• Lee, H. J., K. M. Jung, Y. Z. Huang, L. B. Bennett, J. S. Lee, L. Mei, and T. W. Kim. 2002. Presenilin-dependent gamma-secretase-like intramembrane cleavage of ErbB4. J. Biol. Chem. 277:6318–6323.
   PubMed Web of Science ®Google Scholar
• Lin, Y. Z., and G. M. Clinton. 1991. A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells. Oncogene 6:639–643.
   PubMed Web of Science ®Google Scholar
• Linggi, B., and G. Carpenter. 2006. ErbB-4 s80 intracellular domain abrogates ETO2-dependent transcriptional repression. J. Biol. Chem. 281:25373–25380.
   PubMedGoogle Scholar
• Liu, P. C., X. Liu, Y. Li, M. Covington, R. Wynn, R. Huber, M. Hillman, G. Yang, D. Ellis, C. Marando, K. Katiyar, J. Bradley, K. Abremski, M. Stow, M. Rupar, J. Zhuo, Y. L. Li, Q. Lin, D. Burns, M. Xu, C. Zhang, D. Q. Qian, C. He, V. Sharief, L. Weng, C. Agrios, E. Shi, B. Metcalf, R. Newton, S. Friedman, W. Yao, P. Scherle, G. Hollis, and T. C. Burn. 2006. Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells. Cancer Biol. Ther. 5:657–664.
   PubMed Web of Science ®Google Scholar
• Miller, L. D., J. Smeds, J. George, V. B. Vega, L. Vergara, A. Ploner, Y. Pawitan, P. Hall, S. Klaar, E. T. Liu, and J. Bergh. 2005. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc. Natl. Acad. Sci. USA 102:13550–13555.
   PubMed Web of Science ®Google Scholar
• Molina, M. A., J. Codony-Servat, J. Albanell, F. Rojo, J. Arribas, and J. Baselga. 2001. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 61:4744–4749.
   PubMed Web of Science ®Google Scholar
• Molina, M. A., R. Saez, E. E. Ramsey, M. J. Garcia-Barchino, F. Rojo, A. J. Evans, J. Albanell, E. J. Keenan, A. Lluch, J. Garcia-Conde, J. Baselga, and G. M. Clinton. 2002. NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin. Cancer Res. 8:347–353.
   PubMed Web of Science ®Google Scholar
• Muller, W. J., E. Sinn, P. K. Pattengale, R. Wallace, and P. Leder. 1988. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54:105–115.
   PubMed Web of Science ®Google Scholar
• Ni, C. Y., M. P. Murphy, T. E. Golde, and G. Carpenter. 2001. Gamma-secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 294:2179–2181.
   PubMed Web of Science ®Google Scholar
• Padua, D., X. H. Zhang, Q. Wang, C. Nadal, W. L. Gerald, R. R. Gomis, and J. Massague. 2008. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133:66–77.
   PubMed Web of Science ®Google Scholar
• Pawitan, Y., J. Bjohle, L. Amler, A. L. Borg, S. Egyhazi, P. Hall, X. Han, L. Holmberg, F. Huang, S. Klaar, E. T. Liu, L. Miller, H. Nordgren, A. Ploner, K. Sandelin, P. M. Shaw, J. Smeds, L. Skoog, S. Wedren, and J. Bergh. 2005. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. 7:R953–R964.
   PubMed Web of Science ®Google Scholar
• Pupa, S. M., S. Menard, D. Morelli, B. Pozzi, G. De Palo, and M. I. Colnaghi. 1993. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene 8:2917–2923.
   PubMed Web of Science ®Google Scholar
• Saez, R., M. A. Molina, E. E. Ramsey, F. Rojo, E. J. Keenan, J. Albanell, A. Lluch, J. Garcia-Conde, J. Baselga, and G. M. Clinton. 2006. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin. Cancer Res. 12:424–431.
   PubMed Web of Science ®Google Scholar
• Scaltriti, M., F. Rojo, A. Ocana, J. Anido, M. Guzman, J. Cortes, S. Di Cosimo, X. Matias-Guiu, S. Ramon y Cajal, J. Arribas, and J. Baselga. 2007. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J. Natl. Cancer Inst. 99:628–638.
   PubMed Web of Science ®Google Scholar
• Shigematsu, H., T. Takahashi, M. Nomura, K. Majmudar, M. Suzuki, H. Lee, I. I. Wistuba, K. M. Fong, S. Toyooka, N. Shimizu, T. Fujisawa, J. D. Minna, and A. F. Gazdar. 2005. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 65:1642–1646.
   PubMed Web of Science ®Google Scholar
• Siegel, P. M., D. L. Dankort, W. R. Hardy, and W. J. Muller. 1994. Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol. Cell. Biol. 14:7068–7077.
   PubMed Web of Science ®Google Scholar
• Siegel, P. M., and W. J. Muller. 1996. Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation. Proc. Natl. Acad. Sci. USA 93:8878–8883.
   PubMed Web of Science ®Google Scholar
• Siegel, P. M., E. D. Ryan, R. D. Cardiff, and W. J. Muller. 1999. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J. 18:2149–2164.
   PubMed Web of Science ®Google Scholar
• Ursini-Siegel, J., B. Schade, R. D. Cardiff, and W. J. Muller. 2007. Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat. Rev. Cancer 7:389–397.
   PubMed Web of Science ®Google Scholar
• Vidal, G. A., A. Naresh, L. Marrero, and F. E. Jones. 2005. Presenilin-dependent gamma-secretase processing regulates multiple ERBB4/HER4 activities. J. Biol. Chem. 280:19777–19783.
   PubMed Web of Science ®Google Scholar
• Wang, S. C., H. C. Lien, W. Xia, I. F. Chen, H. W. Lo, Z. Wang, M. Ali-Seyed, D. F. Lee, G. Bartholomeusz, F. Ou-Yang, D. K. Giri, and M. C. Hung. 2004. Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell 6:251–261.
   PubMed Web of Science ®Google Scholar
• Williams, C. C., J. G. Allison, G. A. Vidal, M. E. Burow, B. S. Beckman, L. Marrero, and F. E. Jones. 2004. The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone. J. Cell Biol. 167:469–478.
   PubMedGoogle Scholar
• Xia, W., L. H. Liu, P. Ho, and N. L. Spector. 2004. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 23:646–653.
   PubMed Web of Science ®Google Scholar
• Yarden, Y., and M. X. Sliwkowski. 2001. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2:127–137.
   PubMed Web of Science ®Google Scholar
• Yuan, C. X., A. L. Lasut, R. Wynn, N. T. Neff, G. F. Hollis, M. L. Ramaker, M. J. Rupar, P. Liu, and R. Meade. 2003. Purification of Her-2 extracellular domain and identification of its cleavage site. Protein Expr. Purif. 29:217–222.
   PubMed Web of Science ®Google Scholar
• Zabrecky, J. R., T. Lam, S. J. McKenzie, and W. Carney. 1991. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J. Biol. Chem. 266:1716–1720.
   PubMed Web of Science ®Google Scholar